Form 8-K Arcus Biosciences, Inc. For: Feb 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy
February 26, 2025 6:06 AM ESTH.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (NYSE: RCUS) from Neutral to Buy with a price target of $24.00.
The analyst comments "Initial cas + cabo data expected in mid-2025; we are increasingly positive on opportunity given cas efficacy vs belzutifan. The ARC-20 study evaluating casdatifan (cas) monotherapy and in combo with other agents in clear cell renal cell carcinoma (ccRCC) has enrolled ~40 patients in the cas + cabozantinib (cabo) cohort, which is meant to evaluate the same combo and patient population as the Phase 3 PEAK-1 study expected to initiate in 2Q25... More
